LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.NaturePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41407860无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41421462无 PMCID | 2026-Apr | 0.90 | The study meets the criteria for oncology, human, randomized, phase III, and drug intervention. However, it is excluded because the primary result is a cost/economic analysis, which does not include a time-to-event efficacy endpoint as required for inclusion. | 无 KM 图 |
| Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.Clin Microbiol InfectPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41429349无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.Muscle Nerve疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:FIGURE 1:图注未提示 KM 曲线。 | PMID 41432316PMC12969958 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial.Am J OphthalmolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41485727无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41486043无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.Muscle Nerve疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线。 | PMID 41517964PMC12969971 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.Stroke疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线。 | PMID 41527826PMC13003939 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Validation of the Novel Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire-Caregiver Version in EoE KIDS.J Allergy Clin Immunol PractPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41534558无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.Cancer Sci | PMID 41536071PMC13045266 | 2026-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41544637无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.Muscle NervePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41553108无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer.Breast | PMID 41581361PMC12860362 | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.Cancer Sci | PMID 41611341PMC13045390 | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41621679无 PMCID | 2026-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41629425无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41644383无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.J Dermatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线;FIGURE 5:图注未提示 KM 曲线。 | PMID 41645877PMC13075526 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial.BJU Int疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:生活质量量表图;Fig. 3:森林图/亚组分析图。 | PMID 41667130PMC12962842 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.J Prev Alzheimers Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。 | PMID 41689888PMC12925093 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial.Neuromuscul DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41691937无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41692019无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of polymer oxygenated alginate dressings for healing skin graft donor areas: A phase III randomized controlled trial.BurnsPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41713054无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.Hypertension疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线;Figure 3.:森林图/亚组分析图。 | PMID 41717679PMC13001893 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.Lancet Diabetes Endocrinol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:身体组成变化图。 | PMID 41730814PMC13220893 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.J Clin LipidolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41735092无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study.J Anxiety DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41763071无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41763237无 PMCID | 2026-Apr | 0.85 | Eligible oncology Phase III randomized trial with primary results, but excluded because it lacks a drug intervention (both arms involve procedural/interventional management with talc, a device/drug, but the intervention under study is the addition of an IPC, which is a device, not a novel drug) and the primary efficacy endpoints are not time-to-event outcomes (hospital stay and dyspnoea scores). | 无 KM 图 |
| Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial).Ann Rheum Dis入排复审未纳入:The study is a randomized Phase III trial of a TNF inhibitor (ozoralizumab) for rheumatoid arthritis. It is not an oncology study. The primary endpoint is a categorical outcome (proportion maintaining low disease activity), not a time-to-event endpoint (e.g., OS, PFS, DFS, etc.) with Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort. | PMID 41763966无 PMCID | 2026-Apr | 0.95 | The study is a randomized Phase III trial of a TNF inhibitor (ozoralizumab) for rheumatoid arthritis. It is not an oncology study. The primary endpoint is a categorical outcome (proportion maintaining low disease activity), not a time-to-event endpoint (e.g., OS, PFS, DFS, etc.) with Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort. | 无 KM 图 |
| Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.Nat MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41781546无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Risk factors for recurrence of vulvar high-grade squamous intra-epithelial lesions: long-term follow-up of the PITVIN Study (primary imiquimod vs surgery for vulvar intra-epithelial neoplasia).Int J Gynecol CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41791272无 PMCID | 2026-Apr | 0.95 | The report is an original long-term follow-up of a randomized Phase III trial in human oncology (vulvar HSIL) with a drug intervention (imiquimod). However, the primary endpoint analyzed is recurrence incidence (a binary outcome) with percentages and p-values, not a time-to-event analysis (Kaplan-Meier curves or hazard ratios for OS, PFS, DFS, etc.). Therefore, it does not meet the cohort's requirement for a time-to-event efficacy endpoint. | 无 KM 图 |
| A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.ESMO Open | PMID 41812622PMC12995827 | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41825453无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41831471无 PMCID | 2026-Apr | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图。 | PMID 41850040PMC13015651 | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.Eur J Neurol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线。 | PMID 41913562PMC13140992 | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.Future Oncol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other。 | PMID 41979035PMC13089917 | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.Int J Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42015879无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial.JCO Glob Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42024845无 PMCID | 2026-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Development and Validation of Flow Cytometry-Based Method to Quantify CD34/CD45+ Cells as a Release Criterion of Clinical-Grade Products for a Phase III Clinical Trial.Cytometry A入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42071167无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Treating maternal mental health problems with an app-based program: A randomized control trial of the Building Emotional Awareness and Mental Health (BEAM) program, for mothers of young children.J Consult Clin PsycholPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42080862无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.Curr Med Res OpinPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42262249无 PMCID | 2026-Apr | 0.85 | This is a Phase III randomized trial reporting on patient-reported outcomes (PROs) and quality-of-life time-to-deterioration, not the traditional primary/secondary oncologic time-to-event endpoints (OS, PFS, etc.) required for the Kaplan-Meier digitization cohort. | 无 KM 图 |
| Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.Curr Med Res OpinPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42287159无 PMCID | 2026-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.BMJ | PMID 41916649PMC13036590 | 2026-Mar-31 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41763229无 PMCID | 2026-Mar-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41875914无 PMCID | 2026-Mar-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线。 | PMID 41397287PMC13123421 | 2026-Mar-26 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::CONSORT/入组流程图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图。 | PMID 41880612PMC13020640 | 2026-Mar-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace).Int J Behav Nutr Phys ActPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41882725PMC13154525 | 2026-Mar-26 | 0.85 | While the metadata confirms a human oncology Phase III randomized trial, the abstract describes a secondary analysis of neighborhood environment and physical activity outcomes, not the primary or key time-to-event efficacy outcomes (e.g., survival, progression) required for inclusion in this digitization cohort. | 无 KM 图 |
| Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.Pituitary疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:身体组成变化图;Fig. 3:身体组成变化图。 | PMID 41879875PMC13017995 | 2026-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |